Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 3, 2007, Pages 233-248

  Agrawal, D ^a   Rukkannagari, S ^b   Kethu, S R ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b Kent Hospital   (United States)

Author keywords

Inflammatory bowel diseases, immunology; Inflammatory bowel diseases, physiopatology; Rheumatology

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; BECLOMETASONE; BENZOCAINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; ETANERCEPT; FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARATHYROID HORMONE; POTASSIUM IODIDE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TERAPARATIDE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ANEMIA; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; APHTHOUS STOMATITIS; ARTHRITIS; AUTOIMMUNITY; BONE DENSITY; CHOLELITHIASIS; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG MEGADOSE; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; FISTULA; GENETIC LINKAGE; GENOTYPE; HEREDITY; HUMAN; IRIDOCYCLITIS; KINESIOTHERAPY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MONOTHERAPY; MORBIDITY; NEPHROLITHIASIS; NEPHROSTOMY; OBSTRUCTIVE UROPATHY; OSTEOPOROSIS; PATHOGENESIS; PHENOTYPE; PHYSIOTHERAPY; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; REVIEW; RISK FACTOR; SACROILIITIS; STOMATITIS; THROMBOEMBOLISM; ULCERATIVE COLITIS; UVEITIS; VITAMIN SUPPLEMENTATION;

BILE DUCT DISEASES; EYE DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; MUSCULOSKELETAL DISEASES; SKIN DISEASES; UROLOGIC DISEASES;

EID: 36749006135     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
2. Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn's disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
3. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34.
4. Ricart E, Panaccione R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10:207-14.
5. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease. New insights into autoimmune pathogenesis. Dig Dis Sci 1999;44:1-13.
6. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22.
7. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82.
8. Barreiro-de Acosta M, Dominguez-Munoz JE, Nunez-Pardo de Vera MC, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol 2007;19:73-8.
9. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006;40:467-75.
10. Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996;38:738-41.
11. Peeters H, Vander Cruyssen B, Laukens D, Coucke P, Marichal D, Van Den Berghe M et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004;63:1131-4.
12. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-8.
13. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150-7.
14. Orchard TR, Wordsworth BP, Jewel DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387-91.
15. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002;46:1-6.
16. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002;97:2688-90.
17. Palm O, Mourn B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002;29:511-5.
18. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31.
19. Scott WW Jr, Fishman EK, Kuhlman JE, Caskey CI, O'Brien JJ, Walia GS et al. Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/ clinical correlation. Skeletal Radiol 1990;19:207-10.
20. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-40.
21. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
22. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
23. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
24. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J et al. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondylarthritis. J Rheumatol 2003;30:1356-63.
25. Van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125:1591-7.
26. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
27. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
28. Schoon EJ, van Nunen AB, Wouters RS, Stockbrügger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000;232:43-7.
29. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000;133:795-9.
30. Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003;1:465-73.
31. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002;123:468-75.
32. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
33. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000;46:176-81.
34. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004;53:251-5.
35. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin /RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
36. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
37. De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:397-404.
38. Buchman AL. Bones and Crohn's: problems and solutions. Inflamm Bowel Dis 1999;5:212-27.
39. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003;14:77-81.
40. Requena L, Requena C. Erythema nodosum. Dermatol Online J 2002;8:4.
41. Fleisher M, Rubin S, Levine A. Infliximab in the treatment of steroid refractory erythema nodosum of IBD. Gastroenterology 2002;122 Suppl 1:A618.
42. Callen JP. Pyoderma gangrenosum. Lancet 1998:351:581-5.
43. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31.
44. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005;25:406-10.
45. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7.
46. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-83.
47. Monsen U, Sorstad J, Hellers G, Johannson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711.
48. Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis 2007 Jan 30 [Epub ahead of print]
49. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. Ophthalmology 1984;91:63-173.
50. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997;115:61-4.
51. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6.
52. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9.
53. Schrumpf E, Fausa O, Elgjo K, Kolmannskog F. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988;8:201-9.
54. Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van Erpecum KJ et al. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol 2005;11:7-16.
55. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-64.
56. Broome U, Olsson R, Lindstom E, Loof L, Almer S, Prytz H et al. Natural history and prognostic in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
57. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
58. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22: 1404-8.
59. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308-12.
60. Fraquelli M, Losco A, Visentin S, Cesana BM, Pometta R, Colli A et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 2001;161:2201-4.
61. Kethu SR, Feller ER. Gallstones and cholecystitis. In: Leppert PC, Peipert JF, editors. Primary care for women. Philadelphia: Lippincott, Williams & Wilkins; 2004:440-5.
62. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:44S-49S.
63. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001;96:2296-8.
64. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-7.
65. Quera R, Shanahan F. Thromboembolism - an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004;99:1971-3.
66. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.
67. Novacek G, Haumer M, Schima W, Müller C, Miehsler W, Polterauer P et al. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis 2004;10:430-5.
68. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.
69. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997;90:183-8.
70. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542-8.
71. Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:266-72.
72. Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:62-7.
73. Shield DE, Lytton B, Weiss RM, Brandslund I, Munkholm P, Hey H. Urologic complications of inflammatory bowel disease. J Urol 1976;115:701-6.
74. Ben-Ami H, Ginesin Y, Behar DM, Fischer D, Edoute Y, Lavy A. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can J Gastroenterol 2002;16:225-9.
75. Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:433-6.
76. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998;93:504-14.
77. McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002;89:835-41.
78. Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl 2002;74:61-4.
79. Siminovitch JM, Fazio VW. Ureteral obstruction secondary to Crohn's disease: a need for ureterolysis? Am J Surg 1980;139:95-8.
80. Sato S, Sasaki I, Naito H, Funayama Y, Fukushima K, Shibata C et al. Management of urinary complications in Crohn's disease. Surg Today 1999;29:713-7.
81. Kyle J. Urinary complications of Crohn's disease. World J Surg 1980;4:153-60.
82. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002;97:2022-5.
83. Songur N, Songur Y, Tüzün M, Dogan I, Tüzün D, Ensari A et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003;37:292-8.
84. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:104-15.
85. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007;131:524-32.
86. Higenbottam T, Cochrane GM, Clark TJ, Turner D, Millis R, Seymour W. Bronchial disease in ulcerative colitis. Thorax 1980;35:581-5.
87. Lossos A, River Y, Eliakim A, Steiner I. Neurological aspects of inflammatory bowel disease. Neurology 1995;45(3 Pt 1):416-21.
88. Kimura K, Hunter SF, Thollander MS, Loftus EV, Melton LJ, O'Brien PC et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000;75:802-6.
89. Hoffmann RM, Kruis W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:140-7.
90. Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T et al. Amyloidosis and inflammatory bowel disease: a 50-year experience with 25 patients. Medicine (Baltimore) 1992;71:261-70.
91. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001;7:295-300.
92. Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001;15:363-9.
93. Dhiman RK, Poddar U, Sharma BC, Arora P, Saraswat VA, Pandey R et al. Membranous glomerulonephritis in association with ulcerative colitis. Indian J Gastroenterol 1998;17:62.
94. Hyttinen L, Kaipiainen-Seppanen O, Halinen M. Recurrent myopericarditis in association with Crohn's disease. J Intern Med 2003;253:386-8.
95. Stasinopoulou P, Kaziani A, Mantzaris G, Roussos A, Skoutelis A. Parallel manifestation of Crohn's disease and acute pericarditis: a report of two cases. Int J Colorectal Dis 2007 Jun 2; [Epub ahead of print].